Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 3,624 Shares

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 3,624 shares of the firm’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $46.66, for a total transaction of $169,095.84. Following the completion of the transaction, the director now owns 356,022 shares in the company, valued at $16,611,986.52. The trade was a 1.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Pro-Dex Stock Performance

NASDAQ PDEX opened at $44.33 on Friday. The company’s fifty day moving average is $48.16 and its two-hundred day moving average is $32.58. Pro-Dex, Inc. has a 52-week low of $16.18 and a 52-week high of $59.60. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.41 and a quick ratio of 1.94. The firm has a market capitalization of $144.47 million, a price-to-earnings ratio of 28.79 and a beta of 0.56.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on PDEX shares. Ascendiant Capital Markets raised their price target on Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, November 11th. StockNews.com raised Pro-Dex from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 14th.

Institutional Investors Weigh In On Pro-Dex

Institutional investors have recently added to or reduced their stakes in the company. FMR LLC lifted its position in shares of Pro-Dex by 34.9% in the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after acquiring an additional 1,028 shares during the period. Ritholtz Wealth Management bought a new position in Pro-Dex in the fourth quarter worth $572,000. Renaissance Technologies LLC boosted its stake in Pro-Dex by 7.9% during the second quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after buying an additional 900 shares in the last quarter. Bard Associates Inc. increased its holdings in Pro-Dex by 17.6% in the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock valued at $406,000 after buying an additional 2,031 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Pro-Dex by 2.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock valued at $740,000 after buying an additional 529 shares in the last quarter. 15.28% of the stock is owned by institutional investors and hedge funds.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.